- Home
- RLAY vs RVPH Comparison
RLAY vs RVPH Comparison
Compare RLAY & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- RVPH
- Stock Information
- Founded
- RLAY 2015
- RVPH 2006
- Country
- RLAY United States
- RVPH United States
- Employees
- RLAY N/A
- RVPH N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- RVPH Health Care
- Exchange
- RLAY Nasdaq
- RVPH Nasdaq
- Market Cap
- RLAY 576.1M
- RVPH 32.8M
- IPO Year
- RLAY 2020
- RVPH N/A
- Fundamental
- Price
- RLAY $3.60
- RVPH $0.39
- Analyst Decision
- RLAY Strong Buy
- RVPH Strong Buy
- Analyst Count
- RLAY 11
- RVPH 5
- Target Price
- RLAY $18.40
- RVPH $9.00
- AVG Volume (30 Days)
- RLAY 1.6M
- RVPH 2.5M
- Earning Date
- RLAY 08-05-2025
- RVPH 08-13-2025
- Dividend Yield
- RLAY N/A
- RVPH N/A
- EPS Growth
- RLAY N/A
- RVPH N/A
- EPS
- RLAY N/A
- RVPH N/A
- Revenue
- RLAY $7,679,000.00
- RVPH N/A
- Revenue This Year
- RLAY $14.31
- RVPH N/A
- Revenue Next Year
- RLAY N/A
- RVPH N/A
- P/E Ratio
- RLAY N/A
- RVPH N/A
- Revenue Growth
- RLAY N/A
- RVPH N/A
- 52 Week Low
- RLAY $1.78
- RVPH $0.30
- 52 Week High
- RLAY $10.72
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- RLAY 62.39
- RVPH 31.05
- Support Level
- RLAY $3.10
- RVPH $0.30
- Resistance Level
- RLAY $3.37
- RVPH $0.83
- Average True Range (ATR)
- RLAY 0.24
- RVPH 0.07
- MACD
- RLAY 0.02
- RVPH -0.04
- Stochastic Oscillator
- RLAY 80.52
- RVPH 16.04
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.